Efficacy and Safety of Morinda Officinalis Oligose Capsule in the Treatment of Mild or Moderate Depression

KONG Qing-mei,SHU Liang,ZHANG Hong-yan,JIAO Fu-ying,HAN Zu-cheng,WANG Jian,DU Bo,SHI Jian-guo,WANG Xiao-ping,AI Chang-shan,GAO Cheng-ge,LI ling-zhi,HUANG Lan

DOI: https://doi.org/10.3969/j.issn.1001-6821.2011.03.003

2009-01-01

Abstract:Objectives: To evaluate the efficacy and safety of morinda officinalis oligose capsule in the treatment mild or moderate depressive disorder.Methods: In a randomized,double-blind,double-dummy,multicenter and fluoxetine controlled clinical trial,356 subjects were enrolled and randomly divided into 3 groups.The patients were treated with high-dose(n=119) and low-dose of morinda officinalis oligose capsule(n=119),or fluoxetine hydrochloride tablets(n=118,control).Results: The response rates were 70.34%(high-dose group),66.38%(low-dose group) and 68.91%(control group) respectively;no significant difference was found among 3 groups(F=0.197,P=0.82).At the end point,the scores of HAMD-17 decreased from baseline were 11.6(4.6),11.8(4.0) and 11.9(4.1),respectively.Non-inferiority test with the criterion of 15% was conducted on the efficacies of morinda officinalis oligose capsules and fluoxetine hydrochloride tablets,and the result showed non-inferiority of morinda officinalis oligose capsules(P0.05).The incidences of adverse events were 29.41%(high-dose group),19.83%(low-dose group) and 24.17%(controlled group),respectively;there were no significant differences within groups(P=0.22).Conclusion: Morinda officinalis oligose capsule is effective,similar to fluoxetine hydrochloride tablets,and safe in the treatment of mild and moderate depressive episode.